

Molecular Therapeutics of Cancer Research Conference -- 2009

Co-Sponsored by the Cancer Molecular Therapeutics Research Association
& Stanford University

Schedule and Program

(June 23, 2009)

"IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers."

SUNDAY – JULY 19

3:00 pm	Arrival and check-in (Munger Residence)
6:00 pm	<i>Reception / Dinner</i> (Jordan Hall)
7:30 pm - 7:45 pm	Welcome / Introductory Comments Peter Houghton, President CMTRA Branimir I. Sikic, Stanford University Hilary Calvert, Program Chair
7:45 pm - 10 pm	EVENING SESSION: "Is the Concept of Tumor Stem Cells Useful in Developing New Therapies for Common Solid Tumors?" Discussion Leader: Mike Clarke, Stanford University
7.45 – 8:00 pm	Introduction & Overview
8pm – 8.40pm	Speaker – Chuck Stiles, Dana Farber Cancer Institute "Glioma Stem Cells: A Midterm Exam"
8:40 pm – 9:00 pm	Discussion
9:00 pm – 9:40 pm	Speaker – Christopher Heeschen, Ludwig-Maximilians-University, Munich "Molecular characterization and targeted elimination of metastatic pancreatic cancer stem cells"
9:40 pm – 10:00 pm	Discussion
10:00 pm -	<i>Social</i> (Jordan Hall)

MONDAY – JULY 20

7:30 am - 8:30 am	<i>Breakfast</i> (Branner Hall)
8:30 am - 12:30 pm	MORNING SESSION "Targeting p53" Discussion Leader: Hilary Calvert, Northern Institute for Cancer Research, University of Newcastle, UK
8:30 – 8:45 am	Notices
8:45 – 9:00 am	Introduction

9:00 – 9:40 am	Speaker – Geoff Wahl, Salk Institute “Understanding p53's negative regulators to develop more effective p53-activating therapies”
9:40 – 10:00 am	Discussion
10:00 - 10:30 am	<i>Coffee Break</i>
10:30 – 11:10 am	Speaker – Shaomeng Wang, University of Michigan – MDM2/p53 “Reactivation of p53 by targeting MDM2-p53 interaction as a new cancer therapeutic strategy”
11:10 – 11:30 am	Discussion
11:30 – 12:10pm	Speaker – Janine Arts, Ortho Biotech Oncology R&D - Hdm2 Antagonist “JNJ-26854165 – a novel Hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumoral activity against solid malignancies”
12:10 – 12:30 pm	Discussion
12:30 – 1:00 pm	<i>Lunch</i> (Branner Hall)
2:00 – 4:30 pm	AFTERNOON SESSION “Systems Biology & Large Datasets” Discussion Leader: Jeff Trent, Translational Genomics Research Institute, Phoenix
2:00 – 2:15 pm	Introduction
2:15 – 2:55 pm	Speaker - Joe Gray, Lawrence Berkeley National Laboratory “ ‘Omic’ guides to marker guided therapy in breast cancer”
2:55 – 3:15 pm	Discussion
3:15 – 3:55 pm	Speaker – Carlos Caldas, University of Cambridge, UK “Breast Cancer: Genomic landscapes towards individualized therapeutics”
3:55 – 4:15 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social (Jordan Hall)
6:00 - 6:30 pm	<i>Dinner</i> (Branner Hall)
7:30 pm – 9:45 pm	EVENING SESSION “Oncogene Addiction” Discussion Leader: Frank McCormick, University of California, San Francisco
7.30 – 7:45 pm	Introduction
7:45 – 8:25 pm	Speaker – Dean Felsher, Stanford University School of Medicine “Modeling Oncogene Addiction”
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Speaker – Neal Rosen, Memorial Sloan Kettering Feedback redundancy in oncoprotein signaling pathways - basic and clinical implications
9:25 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i> (Jordan Hall)

TUESDAY JULY 21

- 7:30 am - 8:30 am *Breakfast* (Branner Hall)
- 8:30 am - 12:30 pm **MORNING SESSION “DNA Repair in Cancer Therapy”**
Discussion Leader: Alan Eastman, Dartmouth Medical School
- 8:30 – 8:45 am Notices
- 8:45 – 9:00 am Introduction
- 9:00 – 9:40 am Speaker - Karlene Cimprich, Stanford University
“Maintaining genome stability at the replication fork (and beyond)”
- 9:40 – 10:00 am Discussion
- 10:00 – 10:30 am *Coffee Break*
- 10:30 – 11:10 am Speaker – Roger Griffin, Northern Institute for Cancer Research
“Targeting the DNA damage-response pathway in cancer therapy”
- 11:10 – 11:30 am Discussion
- 11:30 – 12:10 pm Speaker – Ruth Plummer, Northern Institute of Cancer Research / University of Newcastle upon Tyne
“An update on the current status of PARP inhibitors in the clinic”
- 12:10 – 12:30 pm Discussion
- 12.30 – 4.30 pm **LUNCH & NETWORKING AFTERNOON**
Stanford University Campus
- 4.30 – 6.00 pm **Poster Session and Social** (Jordan Hall)
- 6:00 - 6:30 pm *Buffet / Dinner* (Branner Hall)
- 7:30 – 9:45 pm **EVENING SESSION “Novel Protein Therapeutic Strategies”**
Discussion Leader: Rob Kramer, Bristol Myers Squibb
- 7:30 – 7:45 pm Introduction
- 7:45 – 8:25 pm Speaker – Paul Polakis, Genentech
“Arming antibodies for cancer therapy”
- 8:25 – 8:45 pm Discussion
- 8:45 – 9:25 pm Speaker – Robert Kramer, Bristol Myers Squibb,
“Dual targeting Adnectins”
- 9:25 – 9:45 pm Discussion
- 9:45 pm – *Social* (Jordan Hall)

WEDNESDAY JULY 22

- 7:30 - 8:30 am *Breakfast* (Branner Hall)
- 8:30 - 11:00 am **MORNING SESSION** “Targeting Transcription Factors – Drugging the Un-drugable”
Discussion Leader: Stephen Neidle, The School of Pharmacy, University of London
- 8:30 – 8:45 am Notices
- 8:45 – 9:00 am Introduction
- 9:00 – 9:40 am Stephen Neidle, University of London
“Targeting transcription factors – Drugging the un-drugable”
- 9:40 – 10:00 am Discussion
- 10:00 – 10:30 am *Coffee Break*
- 10:30 – 11:10 am Speaker – Pilar Blancafort, University of North Carolina
“Remodeling genomes: Epigenetic reprogramming of tumor and stem cells by designed transcription factors”
- 11:10 – 11:30 am Discussion
- 11:30 – 12:30 pm **POSTER PRESENTATIONS – 4 Selected Presenters**
- 12:30 – 1:00pm *Lunch* (Branner Hall)
- 2:00 – 5:45 pm **AFTERNOON SESSION** “IGF1 Active Drugs – Concept to Cure”
Discussion Leader: Neil Gibson, Pfizer
- 2:00 – 2:15 pm Introduction
- 2:15 – 2:55 pm Speaker: Val Macaulay, University of Oxford
“Overview of IGF1 biology”
- 2:55 – 3:15 pm Discussion
- 3:15 – 3:45 pm *Coffee Break*
- 3:45 – 4:25 pm Speaker: Marco Gottardis, Oncology Drug Discovery, Bristol Myers Squibb
“Small molecule inhibitors of the IGFIR/IR kinase family”
- 4:25 – 4:45 pm Discussion
- 4:45 – 5:25 pm Speaker: Antonio Gualberto, Pfizer
“Clinical experience with therapeutic anti-IGF-IR antibodies”
- 5:25 – 5:45 pm Discussion
- 6 – 10 pm ***Farewell Banquet, Stanford Campus Venue***

THURSDAY JULY 23

- 7:30 - 8:30 am *Breakfast* (Branner Hall)
CHECK OUT BY 11AM

SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

**Schering Plough
Bristol Myers Squibb
Hoffman La Roche
Pfizer
Imclone
Amgen
Centocor Ortho Biotech
LEAD Therapeutics
Stanford University**

MOLECULAR THERAPEUTICS OF CANCER 2010 CONFERENCE

**July 18-21, 2010
Princeton University
Princeton, NJ**

**Program Chair: John Lazo
Site Chair: TBD**